Luigi Cattel

Luigi Cattel

Auto-generated profile, based on publicly available information

Luigi Cattel

Department of Drug Science and Technology University of Turin Turin Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2014 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
PMPaola Milla
Paola Milla
CFChiara Fiorito
Chiara Fiorito
FSFrancesco Soria
Francesco Soria
Silvia ArpiccoSilvia Arpicco
Silvia Arpicco
LCLuigi Cattel
Luigi Cattel
PGPaolo Gontero
Paolo Gontero

1 January 2013 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
Franco DosioFranco Dosio
Franco Dosio
Barbara StellaBarbara Stella
Barbara Stella
AFAnnalisa Ferrero
Annalisa Ferrero
CGClaudio Garino
Claudio Garino
DZDaniele Zonari
Daniele Zonari
GRGobetto Roberto
Gobetto Roberto
Transition metal complexes provide a promising avenue for designing new therapeutic and diagnostic agents. In particular, ruthenium(II) polypyridyl complexes are useful for studying cellular uptake, due to their easy synthesis and unique photophysical properties. Dyes are frequently combined with material substrates to modulate their properties, enhance stability, reduce toxicity, and improve delivery. A novel Ru polypyridyl complex linked to a derivative of the natural lipid squalene (Ru-BIPPBI-hx-SQ) is described. Using the solvent displacement method, Ru-BIPPBI-hx-SQ easily self-assembles into nanosized aggregates in aqueous solution, as characterized by dynamic light scattering. The nanoassemblies exhibit long-lived and intense luminescence. Preliminary biological assessment showed them to be non-toxic; they are efficiently and rapidly transported across the cell membrane without requiring its permeabilization. Ru-labeled nanoassemblies are likely to be significant cellular-imaging tools, probing cellular events at very low concentrations. Moreover co-nanoassembly, with drug-derivatives based on squalenoylation technology, including gemcitabine and paclitaxel, has given interesting preliminary results.

11 November 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
LCLuigi Cattel
Luigi Cattel
SGSusanna Giordano
Susanna Giordano
STSara Traina
Sara Traina
TLTommaso Lupia
Tommaso Lupia
SCSilvia Corcione
Silvia Corcione
FCFrancesco Cattel
Francesco Cattel
Severe acute respiratory syndrome coronavirus 2 is associated with a severe respiratory disease in China, that rapidly spread across continents. Since the beginning of the pandemic, available data suggested the asymptomatic transmission and patients were treated with specific drugs with efficacy and safety data not always satisfactory. The aim of this review is to describe the vaccines developed by three companies, Pfizer‐BioNTech, Moderna, and University of Oxford/AstraZeneca, in terms of both technological and pharmaceutical formulation, safety, efficacy, and immunogenicity. A critical analysis of Phases 1, 2, and 3 clinical trial results available was conducted, comparing the three vaccine candidates, underlining their similarities and differences. All candidates showed consistent efficacy and tolerability; although some differences can be noted, such as their technological formulation, temperature storage, which will be related to logistics and costs. Further studies will be necessary to evaluate long‐term effects and to assess the vaccine safety and efficacy in the general population.

15 March 2005 in ChemInform
Verified
Journal Article
Closed access
PDF file
Silvia ArpiccoSilvia Arpicco
Silvia Arpicco
SCSilvana Luciana Canevari
Silvana Luciana Canevari
MCMaurizio Ceruti
Maurizio Ceruti
EGEnrico Galmozzi
Enrico Galmozzi
FRFlavio Rocco
Flavio Rocco
LCLuigi Cattel
Luigi Cattel

15 July 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MAM. Airoldi
M. Airoldi
LCL. Cattel
L. Cattel
Roberto PasseraRoberto Passera
Roberto Passera
CMC. Micari
C. Micari
EFE. Ferrarato
E. Ferrarato
CZC. Zanon
C. Zanon
2059 Background: Combination of gemcitabine (GEM) with oxaliplatin (OXA) is among the most active chemotherapy for advanced and metastatic pancreatic adenocarcinoma. Based on preclinical data, a supra-additive effect was observed when tumor cells were exposed to GEM first and to OXA 24 h later. Study aim was to evaluate clinical benefits and tolerability of GEM-OXA association in MTS/LA pancreatic carcinoma. By administering sequence-dependent combinations of the two drugs (GEM d1-OXA d2 or OXA d1-GEM d2), pharmacokinetic (PK) interactions were also evaluated. Methods: 30 patients (median age 60.7 yr; ECOG PS = 1) affected by MTS (67%) or LA pancreatic carcinoma (33%) were enrolled. Pts received GEM 1,000 mg/m2 as 10 mg/m2/min infusion and OXA 100 mg/m2 as 2 h infusion q 2 wks (median cycles/patient = 10). For PK study, 15 patients (28 cycles) were enrolled following two alternated protocols: A (GEM-OXA) (9 pts, 16 cycles) received 1st-3rd-5th cicle GEM on day 1 and OXA on day 2; B (OXA-GEM) (6 pts, 12 cycles) received OXA in 2nd-4th-6th cycle on day 1 and GEM on day 2. Results: 30 pts were evaluable for response and toxicity. Response rate was 30%, superimposable in LA and MTS pts; 50% of patients had clinical benefit. Median PFS and OS were 5.5 and 9.5 months, with 40% of pts alive at 1 year. Grade 3/4 toxicity per patient: 10% neutropenia and thrombocytopenia, 13% nausea/vomiting, 7% diarrhea and 10% peripheral neuropathy. By evaluating GEM and OXA PK parameters in arms A and B, no statistically significant difference was revealed between two protocols (Mann-Whitney test). GEM AUC and Cl (A vs B, p 0.84 and 0.87); OXA tot AUC and Cl (p 0.87 and 0.80); OXA ultr AUC and Cl (p 0.91 and 0.84). Pt though level progressively accumulated, from 1st to 6th cycle (Cmin 74.7–321.35 ng/ml). Conclusions: This phase II study showed that biweekly GEM-OXA as a first line chemotherapy in MTS/LA pancreatic carcinoma is well tolerated and has a excellent clinical activity. PK profile of both drugs does not show statistically significant differences between GEM-OXA and OXA-GEM alternate schedules. No significant financial relationships to disclose.